Test Price
2,800 AED✅ Home Collection Available
CRYBA4 Gene Cataract Type 23 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM)
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This Next-Generation Sequencing genetic test screens the entire coding region of the CRYBA4 gene to detect pathogenic variants associated with autosomal dominant congenital cataract type 23. It delivers definitive molecular diagnosis with 99.9% analytical sensitivity when performed on blood, extracted DNA, or FTA card samples, supporting personalized surgical and genetic counseling decisions.
| Feature | Our Test (CryBA4 NGS) | Standard Sanger Sequencing |
|---|---|---|
| Precision | 99.9% analytical sensitivity & specificity, full gene coverage | ~98% sensitivity, limited to targeted exons only |
| Method | Next-Generation Sequencing (Illumina NovaSeq, verified by Sanger) | Capillary Electrophoresis (Sanger) – lower throughput |
| Speed (TAT) | 3–4 Weeks | 5–6 Weeks |
Physician Insight & Safety Protocols
“As the lead geneticist overseeing this diagnostic pathway, I emphasize that every CRYBA4 result must be correlated with detailed phenotyping and family history. A positive genetic finding guides early intervention and cascade screening, while a negative result does not rule out other cataract-related genes. Please discuss all results with your ophthalmologist or geneticist before any clinical decision.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Clinical Precautions
⚠️ Medication Warning
Do not discontinue prescribed medication without consulting your doctor. This test does not replace ophthalmic follow-up or routine eye examinations.
Exclusion Criteria & Emergency Red Flags
- Patients with acute ocular infection or trauma – sample collection deferred.
- Anticoagulation therapy not clinically corrected – risk of hematoma from venipuncture.
- Seek immediate ophthalmic assessment if sudden vision loss, severe eye pain, or acute onset of floaters/flashes occur after sample collection.
- This test is not indicated for acquired cataracts without suspected genetic etiology.
Patient FAQ & Clinical Guidance
1. Why do I need a genetic test for congenital cataract when I already have a clinical diagnosis?
Identifying the exact CRYBA4 mutation confirms the inheritance pattern, enables accurate genetic counseling for family members, and often guides the timing of cataract surgery in children.
2. How is the sample collected, and will it be painful for my child?
A small blood draw (similar to a routine vaccination) or a completely painless cheek swab for DNA extraction is used, performed by our pediatric-trained home collection team within minutes.
3. What happens if no mutation is found in the CRYBA4 gene? Does it rule out all risk?
A negative result only excludes mutations in this specific gene; your ophthalmologist may recommend broader panel testing or whole-exome sequencing if clinical suspicion remains high.
UAE Regulatory & Data Privacy Adherence
All clinical data handling and genetic testing procedures strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | CRYBA4 Gene Cataract Type 23 (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeq, Sanger verification) |
| ICD-10-CM Code | Q12.0 (Congenital cataract) |
| LOINC Code | 93219-8 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians